April 18, 2017 | 10 am PT (1pm EDT)

Sponsored by




Webinar Description:

Fundamental mechanistic research into disease processes has led to an increasing appreciation for the ways in which disease progression and treatment outcomes are influenced by patient heterogeneity. Small changes to low abundant proteins in complex matrices can serve as important indices to reveal important clues about a disease on an individual level, but harnessing this promise rests on our ability to accurately and quantitatively measure proteins with high precision.

Who Should Attend

Researchers interested in biomarker research, cardiovascular research, ultrasensitive biomarker research. Scientist/ Technologists, Professor, Doctor. 


Program Agenda (with time): 10:00am-11:00am
10:00am Brief Introduction
10:05-10:50 Presentation
10:50-11:00 Q&A


Dr. Jennifer E. Van Eyk, PhD, FAHA, FISHR,  Professor of Medicine, Cedars-Sinai Medical Center, Advanced Clinical BioSystems Research Institute, Director
Barbra Streisand Women’s Heart Center, Basic Science Director ,  Erika Glazer Endowed Chair in Women’s Heart Health


 Jennifer E. Van Eyk

Jennifer Van Eyk, PhD
Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Her laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.